CD274 and liver disorder: Current guidelines from American Society of Clinical Oncology (ASCO) [1], European Society for Medical Oncology (ESMO) [2], American Association for the Study of Liver Diseases (AASLD) [3] and Japan Society of Hepatology (JSH) [4] recommend first-line combination therapy with atezolizumab (anti-programmed death ligand 1 [PD-L1] antibody) + bevacizumab (anti-vascular endothelial growth factor [VEGF]-A antibody) (Atezo + Bev) or durvalumab (anti-PD-L1 antibody) + tremelimumab (anti-cytotoxic T lymphocyte–associated antigen 4 [CTLA4] antibody) (Durva + Treme) for uHCC patients.